
Program Memorandum

Carriers

Department of Health and
Human Services (DHHS)
HEALTH CARE FINANCING
ADMINISTRATION (HCFA)

Transmittal B-00-22

Date: APRIL 2000

CHANGE REQUEST 1125

SUBJECT: Durable Medical Equipment Carriers (DMERCs) - New Oral Anti-Cancer Drugs Approved for Use by Medicare

The purpose of this Program Memorandum (PM) is to add four oral-anti-cancer drugs to the DMERC list of drugs. VIPS will hard-code the drug NDC codes into the system and common working file (CWF) will add the WW codes.

The drugs are:

- o Busulfan is billed via NDC code 00173-0713-2 and WW020
- o Temozolomide (Temodar) is billed via the following codes:
 - 5mg. NDC 00085-1248-01 and WW002
 - 250mg. NDC 00085-1252-02 and WW003
 - 250mg. NDC 00085-1252-01 and WW004
 - 100mg. NDC 00085-1259-02 and WW005
 - 20mg. NDC 00085-1244-02 and WW006
 - 20mg. NDC 00085-1244-01 and WW007
 - 100mg. NDC 00085-1259-01 and WW008
 - 5mg. NDC 00085-1248-02 and WW009
- o Methotrexate
 - 2.5mg. NDC 51285-0509-02 and WW033
- o Mylan
 - 2.5mg. NDC 00378-0014-50 and WW034

These codes affect the VIPS standard system, the CWF, and the local DMERC systems. The CWF categories affected are: drugs (17) and DMERC submitted (60). Same CWF edits should apply as other oral anti-cancer codes.

The *effective date* of this PM is January 2000.

The *implementation date* for this PM is July 2000.

These instructions should be implemented within your current operating budget.

This PM may be discarded after July 30, 2001.

DMER contractors should contact their appropriate lead regional office project officer with any questions.

HCFA Pub. 60B